← Back to front page
United States · Exchanges & live quotes · Nasdaq

Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance

Published by Nasdaq · United States 1 h ago

(RTTNews) - Telix Pharmaceuticals Ltd. (TLX), a commercial-stage company, reported a 19% increase in group revenue and highlighted key operational achievements for the third…

Read the full article on Nasdaq Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.nasdaq.com)

Also worth reading

OilPrice.com

How Bad Would It Get If China Blocks Rare Earths to America?

 Investopedia

Understanding Prediction Markets Before You Trade

 CoinMarketCap

Stacks (STX) Volatility: No Clear Catalyst for 5.1% Drop

 Cboe Global Markets

State of the Options Industry Q3 2026: Volume Growth Concentrated in Index and ETF Options

 Google Finance

Developer’s guide to implementing MCP apps in Gemini